A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Test set to determine vulnerability.
- Who it may be relevant to
- Registry conditions: Pelvic Fracture, Prostate Cancer, Lung Cancer, Brain Metastasis. Basic parameters: No limits · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer
Interventions
- Other Test set to determine vulnerability
This is a prospective observational study.
Primary outcome measures
- Detected cause of vulnerability [Time frame: Around the time of study procedure]
Eligibility criteria
Inclusion criteria
- Suspected or diagnosed disease
- ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
- Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
- Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
- Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
- Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization
Exclusion criteria
- Not willing or unable to give written consent
- Patient not deemed suitable for the study by the researcher approaching the patient
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Finland · 1 center
- Tampere University Hospital — Tampere
Identifiers
NCT: NCT07740239 · R24006